½ÃÀ庸°í¼­
»óǰÄÚµå
1134164

Æó¼â½Ä ¾à¹° ÀÌ¼Û ½Ã½ºÅÛ(CSTD) ½ÃÀå ¿¹Ãø(-2027³â)

Global Closed System Drug Transfer Device (CSTD) Market Research Report - Forecast till 2027

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Market Research Future | ÆäÀÌÁö Á¤º¸: ¿µ¹® 110 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Æó¼â½Ä ¾à¹° ÀÌ¼Û ½Ã½ºÅÛ(CSTD) ½ÃÀå ±Ô¸ð´Â 2027³â±îÁöÀÇ Á¶»ç ±â°£ Áß 19.10%ÀÇ CAGR·Î ¼ºÀåÇϸç, 2027³â¿¡´Â 89¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¼¼°èÀÇ Æó¼â½Ä ¾à¹° ÀÌ¼Û ½Ã½ºÅÛ(CSTD) ½ÃÀå¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ¿ªÇÐ, ½ÃÀå ºÐ¼®, °æÀï ±¸µµ, ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¸®Æ÷Æ® ÇÁ·Ñ·Î±×

Á¦2Àå ½ÃÀå ¼­·Ð

  • ¼­·Ð
  • ÀüÁ¦¿Í Á¦ÇÑ
    • °¡Á¤
    • Á¦ÇÑ»çÇ×
  • ½ÃÀå ±¸Á¶

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ÇÁ·Î¼¼½º
  • 1Â÷ Á¶»ç
  • 2Â÷ Á¶»ç
  • ½ÃÀå ±Ô¸ð ÃßÁ¤
  • ¿¹Ãø ¸ðµ¨

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ¼­·Ð
  • ÃËÁø¿äÀÎ
    • ¾ÏÁõ·ÊÀÇ À¯º´·ü »ó½Â
    • ÀÇ·á Á¾»çÀÚÀÇ À¯ÇØ ¾à¹°¿¡ ´ëÇÑ Æø·ÎÀÇ Áõ°¡
    • Æó¼â½Ä ¾à¹° ÀÌ¼Û ½Ã½ºÅÛ(CSTD)ÀÇ »ç¿ë¿¡ °üÇÑ ¸î°³ÀÇ ¾ÈÀü °¡À̵å¶óÀΰú ¹ý·ü
  • ¾ïÁ¦¿äÀÎ
    • °íºñ¿ë
    • Æó¼â½Ä ¾à¹° ÀÌ¼Û ½Ã½ºÅÛ(CSTD)ÀÇ »ç¿ë¿¡ °üÇÑ FDA¿¡ ÀÇÇÑ AE(ADVERSE EVENTS) ¹× ¹ýÀûÀÎ °æ°í
  • ±âȸ
    • Æó¼â½Ä ¾à¹° ÀÌ¼Û ½Ã½ºÅÛ(CSTD)ÀÇ ½ÅÈï ½ÃÀå

Á¦5Àå ½ÃÀå ¿äÀÎ ºÐ¼®

  • Porter's Five Forces ºÐ¼®
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀïÀÇ °­µµ
  • °ø±Þ¸Á ºÐ¼®
    • ¿¬±¸°³¹ß
    • Á¦Á¶
    • À¯Åë
    • ¸¶ÄÉÆÃ ÆÇ¸Å
    • ÆÇ¸Å ÈÄ ¸ð´ÏÅ͸µ
  • ÅõÀÚ ±âȸ
  • °¡°Ý ºÐ¼®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
  • ±ÔÁ¦ ¾÷¹«
  • »ý»êºñ¿ë ºÐ¼®
    • ¿øÀç·á ºñ¿ë ºÐ¼®
    • ±â¼ú ºñ¿ë ºÐ¼®
    • ÀΰǺñ ºÐ¼®

Á¦6Àå Æó¼â½Ä ¾à¹° ÀÌ¼Û ½Ã½ºÅÛ(CSTD) ½ÃÀå : À¯Çüº°

  • °³¿ä
    • ¼­·Ð
    • ¹è¸®¾î½Ä
    • ¿©°ú½Ä

Á¦7Àå Æó¼â½Ä ¾à¹° ÀÌ¼Û ½Ã½ºÅÛ(CSTD) ½ÃÀå : Àü´Þº°

  • °³¿ä
    • ¼­·Ð
    • Ŭ·ÎÁîµå ¹é/¶óÀÎ ¾×¼¼½º µð¹ÙÀ̽º
    • Ŭ·ÎÁîµå ¹ÙÀÌ¾Ë ¾×¼¼½º µð¹ÙÀ̽º
    • Ŭ·ÎÁîµå ½Ã¸°Áö ¼¼ÀÌÇÁƼ µð¹ÙÀ̽º

Á¦8Àå Æó¼â½Ä ¾à¹° ÀÌ¼Û ½Ã½ºÅÛ(CSTD) ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • °³¿ä
    • ¼­·Ð
    • Àü¹® ¼¾ÅÍ
    • º´¿ø°ú Ŭ¸®´Ð

Á¦9Àå ¼¼°èÀÇ Æó¼â½Ä ¾à¹° ÀÌ¼Û ½Ã½ºÅÛ(CSTD) ½ÃÀå : Áö¿ªº°

  • ¼­·Ð
  • ¾Æ¸Þ¸®Ä«
    • ºÏ¹Ì
    • ³²¹Ì
  • À¯·´
    • ¼­À¯·´
    • ¼­À¯·´
    • µ¿À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • Àεµ³×½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿°ú ¾ÆÇÁ¸®Ä«
    • Áßµ¿
    • ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ÁÖ¿ä °³¹ß

Á¦11Àå ±â¾÷ °³¿ä

  • BECTON, DICKINSON AND COMPANY
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • EQUASHIELD LLC
  • ICU MEDICAL INC
  • YUKON MEDICAL
  • CORVIDA MEDICAL

Á¦12Àå ºÎ·Ï

  • µð½ºÄ¿¼Ç ºí·çÇÁ¸°Æ®
KSA 22.10.20

Market Overview

The CAGR for the closed system drug transfer devices market is projected to be 19.10% until 2027. The market esteem is projected to be USD 8.95 billion by 2027.

Closed system drug transfer devices are important for specialists since they safeguard them from coincidentally being infused with hazardous drugs. These devices transfer unsafe drugs and their fumes into another system where they are entangled and can't influence individuals.

The closed system drug transfer devices market is encountering an extremely high CAGR predominantly considering the fast expansion in disease cases. As individuals live longer, they are bound to get malignant growth as they age. Additionally, many individuals smoked in their more youthful years. This can and causes different sorts of malignant growth as they age.

The closed system drug transfer devices market esteem is supposed to be USD 1.62 billion every 2027. The CAGR for this market is projected to be 20.27%. This is principally ascribed to areas of strength in a few market fragments.

The closed system drug transfer devices market has not had many restrictions. One of the primary factors that are keeping down development is the high predominance of clinical devices that either doesn't fill in as well as they ought to or don't function as they were intended to. A significant number of these devices will generally spill out hazardous and strong drugs too. At long last, openness to these drugs can make medical care laborers become fruitless rapidly.

Segment overview

The global closed system drug transfer device market is classified in terms of system, application, and end user.

The closed system drug transfer devices market can be divided into the following sub-segments based on application Nursing, Pharmacy, and Veterinary. The closed-system drug transfer devices market can be divided into the following sub-segments based on end-user Distribution channel

Regional Analysis

The North American district has the prevailing market share in the closed-system drug transfer devices market. America overwhelms as far as market share around here. The explanation is that it has a developed and mind-boggling/complex medical services system. Its emergency clinics are likewise a portion of the dominates on the planet. This country likewise burns through huge amount of cash on public and confidential medical services. It likewise has probably the best examination offices on the planet with regards to medication and clinical consideration.

The development rate in the Asia-Pacific district won't be major areas of strength for as on the grounds that the closed-system drug transfer devices market isn't vigorously controlled. Likewise, the states in most Asian countries don't focus on medical services spending, however their spending on medical services has expanded considerably lately.

Major Companies

The major players in the closed system drug transfer devices market include Becton - USA, Dickinson, and Company (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Equashield LLC (U.S.), ICU Medical Inc. (U.S.), Yukon Medical (U.S.), and Corvida Medical (U.S.)

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 REPORT PROLOGUE

2 MARKET INTRODUCTION

  • 2.1 INTRODUCTION 15
  • 2.2 ASSUMPTIONS & LIMITATIONS 15
    • 2.2.1 ASSUMPTIONS 15
    • 2.2.2 LIMITATIONS 15
  • 2.3 MARKET STRUCTURE 15

3 RESEARCH METHODOLOGY

  • 3.1 RESEARCH PROCESS 17
  • 3.2 PRIMARY RESEARCH 18
  • 3.3 SECONDARY RESEARCH 19
  • 3.4 MARKET SIZE ESTIMATION 19
  • 3.5 FORECAST MODEL 20

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION 22
  • 4.2 DRIVERS 23
    • 4.2.1 RISING PREVALENCE OF CANCER CASES 23
    • 4.2.2 INCREASED RISK OF EXPOSURE TO HAZARDOUS DRUGS FOR HEALTHCARE PERSONNEL 23
    • 4.2.3 SEVERAL SAFETY GUIDELINES AND LEGISLATION FOR THE USE OF CSTD 23
  • 4.3 RESTRAINTS 24
    • 4.3.1 HIGH COST 24
    • 4.3.2 ADVERSE EVENTS AND STATUTORY WARNING BY FDA FOR THE USE OF CSTD 24
  • 4.4 OPPORTUNITY 24
    • 4.4.1 EMERGING MARKETS OF CSTD 24

5 MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS 26
    • 5.1.1 BARGAINING POWER OF SUPPLIERS 26
    • 5.1.2 BARGAINING POWER OF BUYERS 27
    • 5.1.3 THREAT OF NEW ENTRANTS 27
    • 5.1.4 THREAT OF SUBSTITUTES 27
    • 5.1.5 INTENSITY OF RIVALRY 27
  • 5.2 SUPPLY CHAIN ANALYSIS 27
    • 5.2.1 R&D 28
    • 5.2.2 MANUFACTURING 28
    • 5.2.3 DISTRIBUTION 28
    • 5.2.4 MARKETING & SALES 28
    • 5.2.5 POST-SALES MONITORING 28
  • 5.3 INVESTMENT OPPORTUNITIES 28
  • 5.4 PRICING ANALYSIS 29
  • 5.5 MARKETING CHANNEL 29
    • 5.5.1 DIRECT MARKETING 29
    • 5.5.2 INDIRECT MARKETING 29
  • 5.6 REGULATORY AFFAIRS 29
  • 5.7 COST OF PRODUCTION ANALYSIS 30
    • 5.7.1 RAW MATERIAL COST ANALYSIS 31
    • 5.7.2 TECHNOLOGY COST ANALYSIS 31
    • 5.7.3 LABOR COST ANALYSIS 31

6 CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

  • 6.1 OVERVIEW 33
    • 6.1.1 INTRODUCTION 33
    • 6.1.2 BARRIER-TYPE 35
    • 6.1.3 FILTRATION-TYPE 35

7 CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

  • 7.1 OVERVIEW 37
    • 7.1.1 INTRODUCTION 37
    • 7.1.2 CLOSED BAG/LINE ACCESS DEVICES 39
    • 7.1.3 CLOSED VIAL ACCESS DEVICES 39
    • 7.1.4 CLOSED SYRINGE SAFETY DEVICES 40

8 CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

  • 8.1 OVERVIEW 42
    • 8.1.1 INTRODUCTION 42
    • 8.1.2 SPECIALTY CENTERS 43
    • 8.1.3 HOSPITALS & CLINICS 44

9 GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY REGION

  • 9.1 INTRODUCTION 46
  • 9.2 AMERICAS 48

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.2.1 NORTH AMERICA 50

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

      • 9.2.1.1 US 52

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

      • 9.2.1.2 CANADA 53

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

      • 9.2.1.3 MEXICO 55

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.2.2 SOUTH AMERICA 56

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

      • 9.2.2.1 BRAZIL 57

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

      • 9.2.2.2 REST OF SOUTH AMERICA 58

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

  • 9.3 EUROPE 60

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.3.1 WESTERN EUROPE 62

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

      • 9.3.1.1 GERMANY 64

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

      • 9.3.1.2 FRANCE 65

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

      • 9.3.1.3 UK 66

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

      • 9.3.1.4 ITALY 68

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

      • 9.3.1.5 SPAIN 69

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

      • 9.3.1.6 REST OF WESTERN EUROPE 70

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.3.2 EASTERN EUROPE 72

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

  • 9.4 ASIA-PACIFIC 74

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.4.1 CHINA 76

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.4.2 INDIA 78

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.4.3 JAPAN 79

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.4.4 AUSTRALIA 81

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.4.5 SOUTH KOREA 82

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.4.6 INDONESIA 84

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.4.7 REST OF ASIA-PACIFIC 85

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

  • 9.5 MIDDLE EAST AND AFRICA 87

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.5.1 MIDDLE EAST 89

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

    • 9.5.2 AFRICA 90

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY TYPE

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY DELIVERY

CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET, BY END USER

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION 93
  • 10.2 KEY DEVELOPMENTS 94

11 COMPANY PROFILE

  • 11.1 BECTON, DICKINSON AND COMPANY 97
    • 11.1.1 COMPANY OVERVIEW 97
    • 11.1.2 FINANCIAL OVERVIEW 97
    • 11.1.3 PRODUCTS/SERVICES OFFERED 98
    • 11.1.4 KEY DEVELOPMENTS 98
    • 11.1.5 SWOT ANALYSIS 98
    • 11.1.6 KEY STRATEGIES 99
  • 11.2 TEVA PHARMACEUTICAL INDUSTRIES LTD 100
    • 11.2.1 COMPANY OVERVIEW 100
    • 11.2.2 FINANCIAL OVERVIEW 100
    • 11.2.3 PRODUCTS/SERVICES OFFERED 101
    • 11.2.4 KEY DEVELOPMENTS 101
    • 11.2.5 SWOT ANALYSIS 101
    • 11.2.6 KEY STRATEGIES 101
  • 11.3 EQUASHIELD LLC 102
    • 11.3.1 COMPANY OVERVIEW 102
    • 11.3.2 FINANCIAL OVERVIEW 102
    • 11.3.3 PRODUCTS/SERVICES OFFERED 102
    • 11.3.4 KEY DEVELOPMENTS 102
    • 11.3.5 SWOT ANALYSIS 103
    • 11.3.6 KEY STRATEGIES 103
  • 11.4 ICU MEDICAL INC 104
    • 11.4.1 COMPANY OVERVIEW 104
    • 11.4.2 FINANCIAL OVERVIEW 104
    • 11.4.3 PRODUCTS/SERVICES OFFERED 105
    • 11.4.4 SWOT ANALYSIS 105
    • 11.4.5 KEY DEVELOPMENTS 105
    • 11.4.6 KEY STRATEGIES 105
  • 11.5 YUKON MEDICAL 106
    • 11.5.1 COMPANY OVERVIEW 106
    • 11.5.2 FINANCIAL OVERVIEW 106
    • 11.5.3 PRODUCTS/SERVICES OFFERED 106
    • 11.5.4 SWOT ANALYSIS 106
    • 11.5.5 KEY DEVELOPMENTS 106
    • 11.5.6 KEY STRATEGIES 106
  • 11.6 CORVIDA MEDICAL 107
    • 11.6.1 COMPANY OVERVIEW 107
    • 11.6.2 FINANCIAL OVERVIEW 107
    • 11.6.3 PRODUCTS/SERVICES OFFERED 107
    • 11.6.4 KEY DEVELOPMENTS 107
    • 11.6.5 SWOT ANALYSIS 107
    • 11.6.6 KEY STRATEGIES 107

12 APPENDIX

  • 12.1 DISCUSSION BLUE PRINT 109
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦